CUTAIA, ORNELLA
 Distribuzione geografica
Continente #
NA - Nord America 1.089
EU - Europa 772
AS - Asia 122
AF - Africa 4
SA - Sud America 1
Totale 1.988
Nazione #
US - Stati Uniti d'America 1.088
IE - Irlanda 214
IT - Italia 148
GB - Regno Unito 135
RU - Federazione Russa 71
CN - Cina 59
SE - Svezia 55
UA - Ucraina 38
SG - Singapore 36
FR - Francia 31
DE - Germania 27
ES - Italia 17
FI - Finlandia 17
VN - Vietnam 13
CH - Svizzera 4
PL - Polonia 4
BE - Belgio 3
IN - India 3
HR - Croazia 2
SK - Slovacchia (Repubblica Slovacca) 2
TR - Turchia 2
ZA - Sudafrica 2
AM - Armenia 1
BD - Bangladesh 1
BO - Bolivia 1
CI - Costa d'Avorio 1
CZ - Repubblica Ceca 1
GR - Grecia 1
HK - Hong Kong 1
IL - Israele 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LV - Lettonia 1
MA - Marocco 1
MY - Malesia 1
PA - Panama 1
PH - Filippine 1
PT - Portogallo 1
Totale 1.988
Città #
Dublin 213
Fairfield 198
Southend 123
Woodbridge 92
Cambridge 84
Ashburn 83
Santa Clara 78
Seattle 72
Wilmington 64
Houston 61
Siena 40
Jacksonville 36
Chandler 35
New York 32
Ann Arbor 30
Singapore 29
Princeton 28
Shanghai 22
San Diego 18
Beijing 17
Málaga 16
Helsinki 14
San Mateo 14
Dong Ket 11
Palermo 9
Dearborn 6
Labico 5
Nanjing 5
San Giovanni Valdarno 5
Boardman 4
Fremont 4
Hounslow 4
Milan 4
Moscow 4
Redwood City 4
Venezia 4
Zurich 4
Asciano 3
Brussels 3
Empoli 3
Florence 3
Lavis 3
London 3
Rome 3
Altamura 2
Bratislava 2
Chiswick 2
Chiusdino 2
Düsseldorf 2
Johannesburg 2
Pistoia 2
San Francisco 2
Sesto Fiorentino 2
Torino 2
Trieste 2
Warsaw 2
Zagreb 2
Abidjan 1
Arezzo 1
Athens 1
Bishkek 1
Brno 1
Changsha 1
Colombo 1
Dhaka 1
Ferentino 1
Figline Valdarno 1
Guangzhou 1
Guiyang 1
Haikou 1
Hefei 1
Hong Kong 1
Jiaxing 1
Jinan 1
Kilburn 1
La Paz 1
Lanzhou 1
Lappeenranta 1
Lisbon 1
Los Angeles 1
Madrid 1
Menderes 1
Newark 1
Ningbo 1
Nuremberg 1
Phoenix 1
Piscataway 1
Reggio Calabria 1
Riga 1
Roseto Degli Abruzzi 1
Scarperia 1
Stagno 1
Tel Aviv 1
Vientiane 1
Wandsworth 1
Yerevan 1
Zhengzhou 1
Totale 1.559
Nome #
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: Results of a phase II study 220
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 186
Immunomodulatory properties of DNA hypomethylating agents: Selecting the optimal epigenetic partner for cancer immunotherapy 164
Fourteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 13–15, 2016 150
Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial 136
Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: Correlation with survival 134
NK- and T-cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti-CTLA-4 therapy 127
“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013 123
“Cancer Bio-Immunotherapy in Siena”: Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015 117
Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications 109
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012 105
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? 91
ICOS expression as immunologic marker in immune activating monoclonal antibodies 82
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study 67
“Cancer Bio-Immunotherapy in Siena”: Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9–11, 2014 66
null 58
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: An open-label, single-arm, phase 2 study 43
Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study 38
Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial 36
Totale 2.052
Categoria #
all - tutte 8.019
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.019


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020344 0 0 0 0 0 0 76 82 74 45 21 46
2020/2021395 15 47 39 42 22 42 20 56 17 45 15 35
2021/2022230 11 43 20 6 9 11 13 9 6 25 36 41
2022/2023243 20 15 39 19 8 44 10 17 24 17 20 10
2023/2024347 16 8 38 16 11 101 117 5 5 5 15 10
2024/2025230 17 20 60 19 76 38 0 0 0 0 0 0
Totale 2.052